AbbVie, oo ah shirkad cilmi-baaris ku salaysan oo caalami ah, shirkad caalami ah oo biopharmaceutical, ayaa ku dhawaaqday Health Canada waxay ogolaatay SKYRIZI® (risankizumab), ee daaweynta bukaannada qaangaarka ah ee qaba xanuunka psoriasis ee firfircoon. Gudaha PsA, SKYRIZI waxa loo isticmaali karaa kaligii ama marka lagu daro dawada caadiga ah ee wax ka beddelka cudurada aan nafleyda ahayn (cDMARD) (tusaale, methotrexate).
"SKYRIZI oo hesha Ogeysiiska U Hogaansanaanta ee daawaynta psoriatic arthritis-ka ee firfircoon waxay siisaa rajo dheeraad ah bukaanka. Natiijooyinka ka soo baxa barnaamijka tijaabada bukaan-socodka ee Wajiga 3 waxay muujinayaan hagaajinta calaamadaha iyo calaamadaha la xidhiidha cudurkan, "ayuu yiri Dr. Kim Alexander Papp, MD, PhD, FRCPC, FAAD, Probity Medical Research.
"AbbVie, waxaan ku dadaaleynaa inaan bedelno heerka daryeelka ee loogu talagalay dadka difaaca jirka ah, waxaanan ku faraxsanahay ogolaanshaha Caafimaadka Kanada ee SKYRIZI ee daaweynta dadka waaweyn ee qaba xanuunka psoriasis ee firfircoon," ayuu yiri Tracey Ramsay, Madaxweyne kuxigeenka iyo Maareeyaha Guud, AbbVie Canada.
Tani waa calaamadii labaad ee SKYRIZI ee Kanada. Bishii Abriil 2019, Health Canada waxay ogolaatay SKYRIZI daaweynta bukaannada qaangaarka ah ee qaba cudurka psoriasis dhexdhexaad ama daran kuwaas oo u sharaxan daawaynta habdhiska ama sawir-qaadista.
